
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HOPE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HOPE and 80,000+ other tickers.
See exactly how HOPE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HOPE and 80,000+ other tickers.
Hope Bancorp, Inc., established in 2000 and headquartered in Los Angeles, California, functions as the parent entity for Bank of Hope. Through its subsidiary, Bank of Hope, it delivers a comprehensive suite of banking solutions to both individuals and small to medium-sized enterprises across the United States. Customers have access to a wide array of deposit accounts, encompassing personal and business checking, money market accounts, savings accounts, certificate of deposits, and individual retirement accounts. The institution's lending portfolio is extensive, covering various financial…

LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that its wholly-owned subsidiary, Bank of Hope, has received all regulatory approvals required to complete the previously announced acquisition of the Commercial Banking Unit of SMBC MANUBANK (“MANUBANK”), a wholly owned subsidiary of SMBC Americas Holdings, Inc. and Sumitomo Mitsui Banking Corporation (“SMBC”). Regulatory approvals have been received from the Federal Deposit Insurance Corporation and the California.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit--

Hope Bancorp delivered a strong Q2 2026, with revenue and adjusted EPS both exceeding analyst expectations and a swing from loss to profit. HOPE's net interest margin expanded to 2.96%, deposits and loans grew, and non-interest income rebounded sharply due to the absence of prior-year securities losses. Despite trading below book value, HOPE's forward P/E of 13.8 and subpar asset quality (ROA 0.71%, ROE 5.76%) limit its attractiveness.

NEW YORK--(BUSINESS WIRE)--Bank of Hope, subsidiary of Hope Bancorp, Inc. (NASDAQ: HOPE), is expanding the ways it connects with customers and community members through a creative branding campaign centered on a sponsorship of 'BTS THE CITY ARIRANG NEW YORK'. Celebrating ‘BTS THE CITY ARIRANG NEW YORK' as people from around the world gather in New York City, this campaign serves as a unique activation targeted at today's consumers who seek meaningful relationships with the brands with which the.